Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    16014883 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Intervention: Drug: BIBW 2992 (Afatinib)
2 Completed OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )

Indicates status has not been verified in more than two years